News & Updates
Filter by Specialty:
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
19 Oct 2023Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis
A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.
Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis
19 Oct 2023Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
18 Oct 2023Is there a need to re-evaluate HbA1c cutoff in premenopausal women?
In an analysis of over a million individuals in England, women aged <50 years had a markedly lower HbA1c distribution than men, suggesting that the application of the current HbA1c reference range may lead to underdiagnosis of type 2 diabetes (T2D) in premenopausal women.